Loading clinical trials...
Loading clinical trials...
An Open Label, Randomized, Two-Period Crossover Study to Evaluate the Safety and Efficacy of the Addition of Alanyl-Glutamine-Dipeptide to Dialysis Solutions in Peritoneal Dialysis (PD) (Ala-Gln in PD)
Conditions
Interventions
Dipeptiven (Alanyl-glutamine-dipeptide)
Locations
1
Austria
Department of Internal Medicine III; Clinical Division of Nephrology and Dialysis; Medical University of Vienna
Vienna, Austria
Start Date
April 1, 2011
Primary Completion Date
March 1, 2012
Completion Date
May 1, 2012
Last Updated
September 11, 2015
NCT07146854
NCT04163614
NCT04580420
NCT06190717
NCT05654103
NCT03994471
Lead Sponsor
Christoph Aufricht
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions